Business Wire

March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London

Del

March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm birth and new ways to prevent it.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180306006632/en/

This March of Dimes Prematurity Research Center at Imperial College London is supported by a grant from Ferring Pharmaceuticals. Both Ferring and March of Dimes are committed to advancing research to help prevent the 15 million preterm births each year worldwide. Preterm birth is responsible for 1.1 million infant deaths each year.1

“We’re delighted that the talented scientists at Imperial College London will join as the sixth March of Dimes Prematurity Research Center to help us get closer to a world in which all babies are born healthy,” said Stacey D. Stewart, president of March of Dimes. “It’s vital that our team is able to share information and findings with colleagues outside of the U.S., in order to accelerate the discovery of solutions to the serious problem of premature birth.”

Globally, too many babies are being born too soon, and too many families are suffering the consequences,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to addressing unmet patient needs in reproductive medicine and women’s health, including the growing rates of preterm birth worldwide. We believe that this new center will accelerate the development of new healthcare solutions that are urgently needed to help babies that are born earlier than expected.

Phillip Bennett, Professor of Obstetrics and Gynaecology at Imperial College London, and the principal investigator of the new Center, said, “We are proud to have been selected to join the March of Dimes Prematurity Research Center family. Imperial College London and its partner hospitals have renowned clinics for supporting women who deliver preterm, as well as a long tradition of ground-breaking research in this area. As London is a truly global city, we are also fortunate to encompass a large and diverse patient population.”

Our teams of world-class scientists will be using the latest technologies, some unique to Imperial, to study how the body recognises and interacts with bacteria and other microbes in the birth canal. This will enable us to develop methods for predicting--and ultimately preventing--preterm birth.”

The March of Dimes European Prematurity Research Center at Imperial College London will be a partnership between the College and three major London hospitals: Queen Charlotte’s and Chelsea, St. Mary’s Hospital, and Chelsea and Westminster. Each of these hospitals deliver around 5,000 babies a year.

The network of March of Dimes Prematurity Research Centers encompasses approximately 200 scientists in numerous fields, including obstetrics, neonatology, genetics and genomics, immunology, engineering, informatics, and social sciences. (NOTE: See below for a complete list of the Prematurity Research Centers).

Each March of Dimes Prematurity Research Center is assigned a theme or research target. The theme selected for Imperial College London is entitled, “Microbe-Host Interactions.” This team of scientists will identify and characterise these complex processes in order to obtain insight into why some women are at higher risk for preterm birth.

About Preterm Birth
Preterm birth (before 37 weeks of pregnancy) and its consequences are the leading cause of death among children under age five worldwide. Babies who survive an early birth often face lifelong health challenges, such as breathing problems, cerebral palsy, and learning disabilities. The preterm birth rate is on the rise in the United States, climbing for a second year in a row in 2016.

Quick viewable link for B-roll footage on preterm birth: https://www.youtube.com/watch?v=FbFhPnJy3B0

To download B-roll footage on preterm birth: http://bit.ly/2GUyWMsMOD-Imperial-broll

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

About Imperial College London
Imperial College London is one of the world's leading universities. The College's 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.

Imperial is the UK's most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry.

About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.

Because premature birth is such a complex problem, with multiple causes, March of Dimes has chosen Prematurity Research Centers and partners who can use different tools and methods to examine the factors involved in different ways. Each center’s work informs and amplifies the work the other centers are pursuing.

The other five March of Dimes Prematurity Research Centers are located at (with date of launch):

• Stanford University School of Medicine (2011);

• Ohio Collaborative (2013);

• Washington University in St. Louis (2014);

• University of Pennsylvania Perelman School of Medicine (2014);

• University of Chicago-Northwestern University-Duke University (2015).

# # #

References
1 Born Too Soon: The Global Action Report on Preterm Birth. (WHO, March of Dimes) 2012.

Contact information

For more information, please contact:
Ferring Pharmaceuticals
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
Imperial College London
Hannah MacLachlan
Head of Communications
+44 (0) 207 594 6704
h.maclachlan@imperial.ac.uk
Kate Wighton
Research Media Officer – Medicine
+44 (0) 207 594 2409
k.wighton@imperial.ac.uk
March of Dimes
Michele Kling
Director of Media Relations
+ 1 (914) 997 4613
mkling@marchofdimes.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Announcement by Viking Corp on Tecnotree22.6.2018 11:09Pressemelding

In the interests of stakeholder transparency, this announcement provides background and context to Viking's file bankruptcy proceedings upon Tecnotree: As many of you will now know, Viking Corp was recently forced to file bankruptcy proceedings upon Tecnotree, which were withdrawn on the 19 June. In the interests of stakeholder transparency, we make this Announcement to provide background and context to this action. Firstly, we would reflect on the recent history of our attempts to partner with Tecnotree and all its stakeholders. Viking launched a Tender Offer (TO), having conducted detailed discussions with the Tecnotree Board and our advisors. On the basis of those discussions, we were very confident that the TO price of 10 cents per share provided truly superior value for shareholders. So did the Tecnotree Board as evidenced by their unanimous recommendation of our Offer and of course, further evidenced by the current prevailing market price. This TO was supported in the most vigoro